Top

American Journal of Cardiovascular Drugs

Published in:

01-12-2013 | Systematic Review

High-Dose Erythropoietin in Acute ST-Segment Elevation Myocardial Infarction: A Meta-Analysis of Randomized Controlled Trials

Authors: Yanting Wen, Jingyan Xu, Xiaodong Ma, Qian Gao

Published in: American Journal of Cardiovascular Drugs | Issue 6/2013

Abstract

Objective

We sought to perform a meta-analysis to evaluate the potential influence of high-dose erythropoietin (EPO) on cardiac function parameters in patients with acute ST-segment elevation myocardial infarction (STEMI).

Methods and Results

By searching PubMed, EMBASE, and the Cochrane Library (up to December 2012), seven randomized controlled trials (RCTs) reporting cardiac functional parameters with a total of 1,250 acute STEMI patients were identified. When applied to patients with acute STEMI, high-dose EPO was relatively safe and no increase in all-caused death and severe adverse effects were indicated. Estimates were pooled from fixed or random effects models. Compared with controls, high-dose EPO resulted in a slight but significant improvement in left ventricular ejection fraction of 1.02 % [95 % confidence interval (CI) 0.17–1.88, P = 0.019, I ² = 0 %] and an improvement in left ventricular end-systolic volume of −4.61 ml (95 % CI −7.64 to −1.58, P = 0.003, I ² = 27.7 %).

Conclusions

Available evidence suggested that high-dose EPO has limited cardio-protective effects in patients with STEMI. However, considering the relatively short follow-up durations and small patient populations in the current RCTs, the effects of high-dose EPO on clinical outcomes in patients with STEMI need to be evaluated in larger prospective RCTs of longer duration.

Andersen HR, Nielsen TT, Rasmussen K, Thuesen L, Kelbaek H, Thayssen P, et al. A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction. N Engl J Med. 2003;349(8):733–42.PubMedCrossRef

Joyeux-Faure M, Godin-Ribuot D, Ribuot C. Erythropoietin and myocardial protection: what’s new? Fundam Clin Pharmacol. 2005;19(4):439–46.PubMedCrossRef

Latini R, Brines M, Fiordaliso F. Do non-hemopoietic effects of erythropoietin play a beneficial role in heart failure? Heart Fail Rev. 2008;13(4):415–23.PubMedCrossRef

Noguchi CT, Wang L, Rogers HM, Teng R, Jia Y. Survival and proliferative roles of erythropoietin beyond the erythroid lineage. Expert Rev Mol Med. 2008;10:e36.PubMedCrossRef

Lipsic E, van der Meer P, Voors AA, Westenbrink BD, van den Heuvel AF, de Boer HC, et al. A single bolus of a long-acting erythropoietin analogue darbepoetin alfa in patients with acute myocardial infarction: a randomized feasibility and safety study. Cardiovasc Drugs Ther. 2006;20(2):135–41 (Sponsored by the International Society of Cardiovascular Pharmacotherapy).PubMedCrossRef

Ozawa T, Toba K, Suzuki H, Kato K, Iso Y, Akutsu Y, et al. Single-dose intravenous administration of recombinant human erythropoietin is a promising treatment for patients with acute myocardial infarction—randomized controlled pilot trial of EPO/AMI-1 study. Circ J. 2010;74(7):1415–23.PubMedCrossRef

Suh JW, Chung WY, Kim YS, Kim KI, Jeon EJ, Cho YS, et al. The effect of intravenous administration of erythropoietin on the infarct size in primary percutaneous coronary intervention. Int J Cardiol. 2011;149(2):210–20.CrossRef

Taniguchi N, Nakamura T, Sawada T, Matsubara K, Furukawa K, Hadase M, et al. Erythropoietin prevention trial of coronary restenosis and cardiac remodeling after ST-elevated acute myocardial infarction (EPOC-AMI): a pilot, randomized, placebo-controlled study. Circ J. 2010;74(11):2365–71.PubMedCrossRef

Binbrek AS, Rao NS, Al Khaja N, Assaqqaf J, Sobel BE. Erythropoietin to augment myocardial salvage induced by coronary thrombolysis in patients with ST segment elevation acute myocardial infarction. Am J Cardiol. 2009;104(8):1035–40.PubMedCrossRef

10.

Ferrario M, Arbustini E, Massa M, Rosti V, Marziliano N, Raineri C, et al. High-dose erythropoietin in patients with acute myocardial infarction: a pilot, randomised, placebo-controlled study. Int J Cardiol. 2011;147(1):124–31.PubMedCrossRef

11.

Najjar SS, Rao SV, Melloni C, Raman SV, Povsic TJ, Melton L, et al. Intravenous erythropoietin in patients with ST-segment elevation myocardial infarction: REVEAL: a randomized controlled trial. JAMA. 2011;305(18):1863–72.PubMedCrossRef

12.

Ott I, Schulz S, Mehilli J, Fichtner S, Hadamitzky M, Hoppe K, et al. Erythropoietin in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomized, double-blind trial. Circulation. 2010;3(5):408–13.PubMed

13.

Voors AA, Belonje AM, Zijlstra F, Hillege HL, Anker SD, Slart RH, et al. A single dose of erythropoietin in ST-elevation myocardial infarction. Eur Heart J. 2010;31(21):2593–600.PubMedCrossRef

14.

Ludman AJ, Yellon DM, Hasleton J, Ariti C, Babu GG, Boston-Griffiths E, et al. Effect of erythropoietin as an adjunct to primary percutaneous coronary intervention: a randomised controlled clinical trial. Heart (British Cardiac Society). 2011;97(19):1560–5.CrossRef

15.

Prunier F, Biere L, Gilard M, Boschat J, Mouquet F, Bauchart JJ, et al. Single high-dose erythropoietin administration immediately after reperfusion in patients with ST-segment elevation myocardial infarction: results of the erythropoietin in myocardial infarction trial. Am Heart J. 2012;163(2):200-7.e1.

16.

Li J, Xu H, Gao Q, Wen Y. Effect of erythropoiesis-stimulating agents in acute ST-segment elevation myocardial infarction: a systematic review. Eur J Clin Pharmacol. 2012;68(5):469–77.PubMedCrossRef

17.

Higgins JP, Green S. Cochrane handbook for systematic reviews of interventions 2008; Version 5.1.0 [updated March 2011]. http://www.cochrane-handbook.org. Accessed Jan 2013.

18.

Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ (Clinical Research Ed) 2003; 327(7414):557–60.

19.

Maiese K, Li F, Chong ZZ. New avenues of exploration for erythropoietin. JAMA. 2005;293(1):90–5.PubMedCrossRef

20.

Lin FK, Suggs S, Lin CH, Browne JK, Smalling R, Egrie JC, et al. Cloning and expression of the human erythropoietin gene. Proc Natl Acad Sci USA. 1985;82(22):7580–4.PubMedCrossRef

21.

Gregory CJ, Eaves AC. Three stages of erythropoietic progenitor cell differentiation distinguished by a number of physical and biologic properties. Blood. 1978;51(3):527–37.PubMed

22.

Maiese K, Chong ZZ, Li F, Shang YC. Erythropoietin: elucidating new cellular targets that broaden therapeutic strategies. Prog Neurobiol. 2008;85(2):194–213.PubMedCrossRef

23.

Henry DH, Bowers P, Romano MT, Provenzano R. Epoetin alfa. Clinical evolution of a pleiotropic cytokine. Arch Intern Med. 2004;164(3):262–76.PubMedCrossRef

24.

Moon C, Krawczyk M, Ahn D, Ahmet I, Paik D, Lakatta EG, et al. Erythropoietin reduces myocardial infarction and left ventricular functional decline after coronary artery ligation in rats. Proc Natl Acad Sci USA. 2003;100(20):11612–7.PubMedCrossRef

25.

Parsa CJ, Matsumoto A, Kim J, Riel RU, Pascal LS, Walton GB, et al. A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest. 2003;112(7):999–1007.PubMed

26.

Mastromarino V, Volpe M, Musumeci MB, Autore C, Conti E. Erythropoietin and the heart: facts and perspectives. Clin Sci (Lond). 2011;120(2):51–63.PubMedCrossRef

27.

Parsa CJ, Kim J, Riel RU, Pascal LS, Thompson RB, Petrofski JA, et al. Cardioprotective effects of erythropoietin in the reperfused ischemic heart: a potential role for cardiac fibroblasts. J Biol Chem. 2004;279(20):20655–62.PubMedCrossRef

28.

Grimm C, Wenzel A, Groszer M, Mayser H, Seeliger M, Samardzija M, et al. HIF-1-induced erythropoietin in the hypoxic retina protects against light-induced retinal degeneration. Nat Med. 2002;8(7):718–24.PubMedCrossRef

29.

Brines M, Grasso G, Fiordaliso F, Sfacteria A, Ghezzi P, Fratelli M, et al. Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor. Proc Natl Acad Sci USA. 2004;101(41):14907–12.PubMedCrossRef

30.

Asaumi Y, Kagaya Y, Takeda M, Yamaguchi N, Tada H, Ito K, et al. Protective role of endogenous erythropoietin system in nonhematopoietic cells against pressure overload-induced left ventricular dysfunction in mice. Circulation. 2007;115(15):2022–32.PubMedCrossRef

31.

Mehta JL. Erythropoietin in cardioprotection: does it have a future or is it all in the past? Cardiovasc Res. 2008;79(4):549–50.PubMedCrossRef

32.

Calvillo L, Latini R, Kajstura J, Leri A, Anversa P, Ghezzi P, et al. Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc Natl Acad Sci USA. 2003;100(8):4802–6.PubMedCrossRef

33.

Hirata A, Minamino T, Asanuma H, Fujita M, Wakeno M, Myoishi M, et al. Erythropoietin enhances neovascularization of ischemic myocardium and improves left ventricular dysfunction after myocardial infarction in dogs. J Am Coll Cardiol. 2006;48(1):176–84.PubMedCrossRef

34.

Heeschen C, Aicher A, Lehmann R, Fichtlscherer S, Vasa M, Urbich C, et al. Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood. 2003;102(4):1340–6.PubMedCrossRef

35.

Tramontano AF, Muniyappa R, Black AD, Blendea MC, Cohen I, Deng L, et al. Erythropoietin protects cardiac myocytes from hypoxia-induced apoptosis through an Akt-dependent pathway. Biochem Biophys Res Commun. 2003;308(4):990–4.PubMedCrossRef

36.

Niccoli G, Andreotti F, Marzo F, Cecchetti S, Santucci E, D’Amario D, et al. Endogenous serum erythropoietin and no-reflow in patients with ST-elevation myocardial infarction. Eur J Clin Invest. 2011;41(11):1210–9.PubMedCrossRef

37.

Riksen NP, Hausenloy DJ, Yellon DM. Erythropoietin: ready for prime-time cardioprotection. Trends Pharmacol Sci. 2008;29(5):258–67.PubMedCrossRef

38.

Macdougall IC, Roberts DE, Coles GA, Williams JD. Clinical pharmacokinetics of epoetin (recombinant human erythropoietin). Clin Pharmacokinet. 1991;20(2):99–113.PubMedCrossRef

39.

Flaharty KK, Caro J, Erslev A, Whalen JJ, Morris EM, Bjornsson TD, et al. Pharmacokinetics and erythropoietic response to human recombinant erythropoietin in healthy men. Clin Pharmacol Ther. 1990;47(5):557–64.PubMedCrossRef

40.

Moon C, Krawczyk M, Paik D, Lakatta EG, Talan MI. Cardioprotection by recombinant human erythropoietin following acute experimental myocardial infarction: dose response and therapeutic window. Cardiovasc Drugs Ther. 2005;19(4):243–50 (Sponsored by the International Society of Cardiovascular Pharmacotherapy).PubMedCrossRef

Title: High-Dose Erythropoietin in Acute ST-Segment Elevation Myocardial Infarction: A Meta-Analysis of Randomized Controlled Trials
Authors: Yanting Wen
Jingyan Xu
Xiaodong Ma
Qian Gao
Publication date: 01-12-2013
Publisher: Springer International Publishing
Published in: American Journal of Cardiovascular Drugs / Issue 6/2013
Print ISSN: 1175-3277
Electronic ISSN: 1179-187X
DOI: https://doi.org/10.1007/s40256-013-0042-3

Keynote webinar | Spotlight on medication adherence

Springer Medicine

High-Dose Erythropoietin in Acute ST-Segment Elevation Myocardial Infarction: A Meta-Analysis of Randomized Controlled Trials

Abstract

Objective

Methods and Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objective

Methods and Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 6/2013

Acknowledgement to Referees

Optimizing Reperfusion in Patients with STEMI: A Critical Evaluation of Pharmacologic and Non-Pharmacologic Strategies

Factors Associated with Undertreatment of Atrial Fibrillation in Geriatric Outpatients with Alzheimer Disease

Comparison of Antiplatelet Effect and Safety of Clopidogrel Napadisilate with Clopidogrel Bisulfate in Coronary Artery Disease Patients: Multi-center, Randomized, Double-blind, Phase IV, Non-inferiority Clinical Trial

Aspirin Discontinuation Syndromes: Clinical Implications of Basic Research Studies

HMG-CoA Reductase Inhibitors in Chronic Kidney Disease